 |
N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide |
|---|---|
| Trade Name | |
| Orphan Indication | TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive and ALK-positive non-small cell lung cancer |
| USA Market Approval | USA |
| USA Designation Date | 2015-02-03 00:00:00 |
| Sponsor | Ignyta, Inc.;11095 Flintkote Avenue, Suite D;San Diego, CA, 92121 |
